Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
KI-3106 is under clinical development by Kuhnil Pharmaceutical and currently in Phase I for Hyperlipidemia. According to GlobalData, Phase I drugs for Hyperlipidemia have a 72% phase transition ...
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.